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Abstract
The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor
receptor (EGFR). Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and
that gefitinib increases the affinity for some cell lines. In this paper, we investigate possible mechanisms behind these
observations. Real-time interaction analysis in LigandTracerH Grey revealed that the HER2 dimerization preventing antibody
pertuzumab clearly modified the binding of
125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of
gefitinib. Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2. Cross-linking
measurements showed that gefitinib increased the amount of EGFR dimers 3.0–3.8 times in A431 cells in the absence of
EGF. In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8–2.2 times by gefitinib, but this effect was
cancelled by pertuzumab. Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431,
U343, SKOV3 and SKBR3. Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered
the different components of the measured interaction and supports EGF binding to multiple binding sites. EGFR and HER2
expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/
dimeric forms of EGFR with unique binding properties. Taken together, we conclude that dimerization explains the varying
affinity of EGF – EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction
characteristics with
125I-EGF.
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Introduction
The extracellular binding of EGF to EGFR (also denoted
ErbB1) triggers signals that are transduced through the cells and
causes cell proliferation. Atypical activity and over-expression of
EGFR is associated with a number of tumors, making it a common
target for cancer research. Although well studied, many questions
still remain unanswered about the interaction of EGF with EGFR,
the resulting signaling and its involvement in cancer.
Apart from EGFR, the epidermal growth factor receptor family
consists of the HER2, HER3 and HER4 receptors. The four
receptors are known to dimerize, as homodimers or as
heterodimers with other members of the family. The presence of
EGFR dimers in EGF unstimulated cells have been discussed for
many years, where some groups claim that EGFR dimers exist
without stimulation [1,2] while the more common belief is that
EGFR dimerization requires a conformation change caused by the
binding of EGF to monomeric EGFR [3,4,5]. Upon receptor
dimerization, the cytoplasmic tyrosine kinase domain is activated
through phosporylation [6]. HER2 is consecutively and ligand
independently activated and is the preferred binding partner of
EGFR [7]. HER2 dimerization with EGFR enhances and
prolongs the downstream signaling caused by EGF binding [8],
possibly due to the endocytosis deficiency of HER2, which in turn
negatively affects the EGFR downregulation [9].
The EGF – EGFR interaction is known to be complex.
Scatchard plots depict the presence of both low affinity and high
affinity receptor populations, the latter less abundant [10,11].
More recent studies presents a difference in affinity to EGF
between the monomeric and homodimeric form of EGFR [12],
where homodimers bind EGF more strongly. Furthermore, the
high affinity population has been pointed out as the primary
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EGFR dimers correspond to the high affinity population observed
in the past.
The use of tyrosine kinase inhibitors (TKI) is a mean of
disrupting the proliferation and anti-apoptotic downstream
signaling [14]. One example is gefitinib (IRESSA
TM) which is
directed towards EGFR and used as therapy against non-small cell
lung cancer [15]. The aim is to inhibit tumor growth, but the
response varies to a large extent between patients [16]. The reason
behind this variation has been extensively investigated and
discussed during the last decade, without much success. Lapatinib
is another TKI targeted towards EGFR and HER2 for HER2
overexpressing mammary tumors [17]. It binds the inactive forms
of EGFR as opposed to gefitinib that stabilize the active
conformation [18,19,20,21]. Gefitinib, but not lapatanib, have
previously been shown to promote dimerization of EGFR. These
dimers are considered non-active and conformationally different
from ligand triggered dimer forms [21].
We have previously investigated the kinetic properties and the
affinity of the
125I-EGF – EGFR interaction in different cell lines
exposed to various treatments (complete or serum free medium, in
the presence or absence of gefitinib) [22]. No effect of gefitinib was
observed in U343 and SKBR3 cells, but it clearly affected the
binding of
125I-EGF in A431 and SKOV3 cells. The overall
affinity increased in both cell lines, but the kinetics properties
(association and dissociation rate) were differently affected between
the two. In addition, the shape of the real-time binding curves
produced in LigandTracer Grey displayed evidence of more than
one EGF binding interaction taking place simultaneously. The
overall affinity was quantified and it was found to vary as much as
40 times between cell lines (from 0.2 nM in SKBR3 to 8 nM in
A431).
The aim of this work was to investigate the biological
mechanism behind the effect of gefitinib on the
125I-EGF –
EGFR interaction and the differences in affinity between hosting
cell lines. We present a detailed interaction analysis study of how
the binding of
125I-EGF to EGFR is affected by tyrosine kinase
inhibitors and the HER2 dimerization preventing antibody
pertuzumab. Real-time binding traces of the interaction together
with cross-linking assays show a connection between the effect of
gefitinib and EGFR dimer levels. We also introduce a novel tool
for binding trace analysis of complex interactions: the Interaction
Map. Having previously been applied to molecular interaction
analysis by SPR [23], this tool shows promise for resolving the
complex results of protein-cell interactions.
Results
Gefitinib and serum free medium does not alter the EGFR
or HER2 expression in A431, U343, SKOV3 or SKBR3 cells
The EGFR and HER2 expression level under different
culturing conditions (complete medium or serum free medium,
with or without gefitinib) was quantified either manually or with
the kinetic extrapolation (KEX) method [24] using LigandTracer
(Table 1). No clear differences were observed between treatments
in any of the four cell lines. The apparent affinity to
125I-EGF
varied greatly between the cell lines, as described previously [22]
and presented in Table 1. For this set of cell lines, there seems to
be some correlation between HER2 and EGFR expression and the
overall affinity, with a higher affinity in cells expressing a large
number of HER2 receptors and fewer EGFR.
Pertuzumab affects the binding of
125I-EGF to SKOV3
cells but not to A431 or U343 cells
The dimerization preventing antibody pertuzumab binding to
HER2 was added to investigate the role of EGFR-HER2
heterodimerization to the measured
125I-EGF interaction, pro-
ducing binding traces presented as representative curves in
Figure 1. Little or no differences were observed for U343 cells
and A431 cells (data not shown). The addition of pertuzumab to
SKOV3 cells modified the binding of
125I-EGF, observed as
differences in curvature, when simultaneously treated with
gefitinib. The increase in affinity caused by gefitinib, observed as
a higher saturation of receptors with the first concentration and a
slower dissociation (Fig. 1C and D, black curves), was essentially
canceled by pertuzumab (Fig. 1C and D, red curves).
The effects of EGF, gefitinib and pertuzumab on EGFR
dimerization in A431 and SKOV3 cells
The amount of dimerized EGFR receptors in A431 and
SKOV3 cells was studied by immunoblots using the reagent BS
3
as a receptorcross-linking agent. The cells were incubated with or
without EGF, fetal calf serum (FCS), gefitinib and pertuzumab
before lysis, as presented in Figure 2 (representative data from one
of four experiments). A presence of EGFR dimers without
stimulation of EGF is seen in both cell lines, although to a higher
extent in SKOV3 where the differences between stimulated and
unstimulated cells are small (Fig. 2A–D, lane 1 and 2). No
differences were observed between cells stimulated with complete
or serum free medium in the presence of gefitinib (Fig. 2A–D, lane
3–4 and 6–7). Detection of b-actin was used as a loading control.
Table 1. The EGFR and HER2 expression of A431, U343, SKOV3 and SKBR3 cells in four culturing conditions.
A431 U343 SKOV3 SKBR3
EGFR HER2 KD, app EGFR HER2 KD, app EGFR HER2 KD, app EGFR HER2 KD, app
Complete medium 2.160.4E6 1.560.1E5 8 nM 6.460.5E5 3.160.6E4 1.4 nM 3.460.6E5 2.060.3E7 0.9 nM 4.160.3E5 5.860.5E6 0.2 nM
Serum free medium 2.260.5E6 1.760.2E5 6.760.6E5 3.560.4E4 1.960.2E5 2.160.05E7 3.560.5E5 7.260.6E6
Gefitinib +complete
medium
2.260.3E6 2.660.5E5 6.961.0E5 2.260.3E4 3.260.6E5 2.360.1E7 4.660.6E5 6.462.6E6
Gefitinib +serum
free medium
1.360.2E6 2.060.5E5 5.360.1E5 2.760.3E4 2.18E+05E5 3.060.4E6 5.760.3E5 6.560.3E6
Estimation of EGFR and HER2 receptors were conducted either manually or by the KEX method using LigandTracer. Estimations of the affinities have been described
previously [22]. Data are presented as mean6S.E (n=226). No clear effects of the treatments on the EGFR and HER2 expression is observed in either of the cell lines.
doi:10.1371/journal.pone.0024739.t001
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treatments.
The intensities of the EGFR monomer and dimer bands were
quantified using ImageJ to study the effect of X (where X was
EGF, gefitinib or pertuzumab) on dimerization. The effect was
calculated as
EffectValueX~
DimerizationX
DimerizationNoX ~
DimerX
MonomerX
DimerNoX
MonomerNoX
where an EffectValue significantly different from 1 signifies an
impact of X on the EGFR dimerization. Another lysate within the
same gel treated identically apart from the exposure of X was used
as the reference (Tables 2 and 3).
Exposure of EGF increased dimerization in A431 cells 3.9 times. No
effect of EGF on EGFR dimerization was observed in SKOV3 cells.
EGFR dimerization in EGF unexposed A431 cells increased
3.0–3.8 times upon gefitinib tratement (Table 2). Gefitinib
increased EGFR dimerization in most of the EGF exposed A431
cells as well, but to a lesser extent (1.4–1.9 times). A significant
effect of gefitinib was observed in EGF treated SKOV3 cells
(p,0.1), with an increase of 1.8–2.2 times. No effect of gefitinib on
EGFR dimerization was detected in EGF untreated SKOV3 cells.
No effect of pertuzumab on the EGFR dimerization in A431
cells was observed (Table 3). In SKOV3 cells, a significant (p,0.1)
disruption of in average 40–60% of the EGFR dimerization was
detected upon pertuzumab treatment.
Lapatinib effects the binding of
125I-EGF to A431 cells in a
different manner than gefitinib
Exposure of lapatinib modified the kinetics of the
125I-EGF–
A431 interaction (Fig. 3A). A fast on–fast off interaction was
observed in all treatments, but the contribution of it increased
when the cells were treated with lapatinib (Fig. 3A, green and
black curves). This resulted in an overall faster interaction during
both association and dissociation. The difference between the
signal height of the first and second concentrations, as indicated by
an arrow, is slightly less when treated with serum free medium
(Fig. 3A, black curves). These alterations were different from the
effects of gefitinib in A431 cells, where the overall affinity
increased upon exposure and the dissociation rate varied between
complete and serum free medium (Fig. 3B, green and black
curves).
The heterogeneity of the binding of
125I-EGF can be
visualized by Interaction Maps
Interaction Map is a mathematical method to decipher a
heterogeneous interaction into its underlying components. It is
based on the main assumption that the binding of a ligand to a
Figure 1. The effect of pertuzumab on the
125I-EGF – SKOV3 interaction. Thebindingof
125I-EGFtoculturedSKOV3cells inLigandTracerGrey,
in the presence (red) or absence (black) of the HER2 dimerization disrupting antibody pertuzumab. The cells were cultured in A) complete medium, B)
serum-free medium, C) complete medium containing 1 mM gefitinib or D) serum free medium with 1 mM gefitinib. The
125I-EGF – SKOV3 interaction is
affected by pertuzumab, most evidently in gefitinib treated cells where the shape of the binding traces is clearly altered. The curves are representative
data from triplicates or quadruplicates and have been normalized to the equilibration level of the second concentration for better comparison.
doi:10.1371/journal.pone.0024739.g001
Gefitinib Induce EGFR Dimers - Affects Interaction
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24739heterogeneous mixture of targets can be expressed as a sum of
interactions [23,25] where each interaction is represented in an
on-off map by its specific pair of recognition (log(ka)) and stability
(log(kd)) coordinates and a color corresponding to the calculated
contribution (warm colors–large contribution).
Interaction Maps were first calculated on simulated data
representing known interaction properties similar to the ones
shown to exist in the EGF-EGFR interaction (Fig. 4), which
verified that the algorithm could accurately resolve a multitude of
different simultaneous interactions. When applied on real
interaction data, the Interaction Maps displayed up to three
different simultaneous interactions in A431 cells (Fig. 5A–C). The
Interaction Map of the binding of
125I-EGF to A431 in complete
medium depicted two interactions: one fast on–fast off, A1, [4.79,
23.25] with a KD of 9 nM and one slow on–slow off, A2
[3.98,24.94], with a KD of 1 nM (Fig. 5A). These two interactions
contributed approximately equally to the measured binding curve.
When exposed to gefitinib in serum free medium (Fig. 5B), the
recognition of the more stable interaction increased slightly from
log(ka): 3.98 (A2) to log(ka): 4.37 (B2), while as the weaker
interaction (A1) remained in position (B1). Furthermore, a fast on–
slow off high affinity interaction (B3) appeared at position
[6.11,25.28], corresponding to a KD of 41 pM. Pertuzumab did
not alter the positions and contributions of the peaks (Fig. 5C,
peaks C1, C2, C3).
The Interaction Maps of SKOV3 cells presented interaction
patterns different to A431 cells. In complete medium two
contributing
125I-EGF–SKOV3 interactions occurred simulta-
neously with approximately the same recognition but different
stability (D1 [5.07,23.48] and D2 [4.85,24.59] (Fig. 5D)). The
more stable interaction D2, with a KD of about 0.4 nM,
contributed to approximately 65% of the measured binding curve.
Upon gefitinib treatment in serum free medium, D2 shifted to a
higher stability (E2 [4.89,25.82]) corresponding to a KD of 20 pM
Figure 2. EGFR dimerization effects of EGF, gefitinib and pertuzumab observed in cross-linking analysis. EGFR targeting antibodies
were used to depict EGFR monomers and dimers on A431 (A and B) and SKOV3 (C and D) lysates. The cells were treated with or without gefitinib and
pertuzumab in complete (+FCS) or serum free medium. The difference between A and B as well as C and D is the stimulation of EGF. EGFR dimers
exist without stimulation of EGF (A–D, lane 1–2), particularly in SKOV3 cells. Gefitinib increases the dimer levels in both cell lines, regardless of other
treatment (A–D, lane 3–4 and 6–7). Pertuzumab does not affect the overall dimer levels of EGFR in A431 cells much (A and B, lane 5–7), but clearly
disrupts EGFR dimerization in SKOV3 (C and D, lane 5–7). The BS
3 free lysates were used as negative controls for the cross-linking assay and the b-
actin band was used as a loading control. This is a representative of one of four experiments.
doi:10.1371/journal.pone.0024739.g002
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interaction D1 was reduced even further (E1). No equivavelent
to the fast on–slow off interaction observed in A431 cells (B3/C3)
appeared in gefitinib treated SKOV3 cells. The addition of
pertuzumab resulted in an interaction pattern (Fig. 5F) resembling
a mixture of the other two Interaction Maps (Fig. 5D and E), with
the more stable interaction F2 somewhere in between the previous
two positions D2 and E2 while as the weaker interaction F1
remained in position (Fig. 5F).
Discussion
The aim of this study was to further investigate the binding of
125I-EGF to EGFR in order to explain previous results which
indicated an impact of the tyrosine kinase inhibitor gefitinib on the
interaction [22]. The study started with the quantification of
EGFR and HER2 expression on the four previously studied cell
lines. The total number of EGFR and HER2 receptors did not
vary at different treatments and can thus not explain the effects of
gefitinib on the EGF binding.
All EGF incubations described in this paper (i.e. in real-time
interaction measurements using LigandTracer and prior to cell
lysis for the cross-linking assay) were performed at room
temperature. Measurements at 37uC would have been more
comparable to the reality inside a body, but the heat triggers
EGFR to internalize upon EGF binding, resulting in processing or
recycling of EGFR. These intracellular processes are difficult to
distinguish from the activities of the membrane bound receptors.
Thus, to make the data analysis manageable, room temperature
were chosen as an adequate alternative to 37uC. The pre-
treatments of gefitinib or pertuzumab before LigandTracer
measurements or cell lysis were all done at 37uC.
The antibody pertuzumab disrupts the dimerization ability of
HER2, creating fewer EGFR–HER2 heterodimers and more
Table 2. The effect of gefitinib on EGFR dimerization in A431 and SKOV3 cells.
A431
Without pertuzumab With pertuzumab
Effect of: Without EGF With EGF Without EGF With EGF
Gefitinib+complete medium 3.661.0* 1.960.1* 3.860.9* 1.660.2*
Gefitinib+serum free medium 3.660.8* 1.460.1* 3.060.6* 1.460.2
SKOV3
Without pertuzumab With pertuzumab
Effect of: Without EGF With EGF Without EGF With EGF
Gefitinib+complete medium 1.260.1* 2.060.1* 1.160.2 2.160.4*
Gefitinib+serum free medium 1.560.1* 1.860.1* 1.260.2 2.260.4*
The intensity of the monomer and dimer Western blot bands were analyzed and compared within gels. The table presents EffectValues, i.e. quotients of dimerization
degrees. Lysates within the same gel treated identically apart from the exposure of gefitinib (with/without FCS) were used as references. Data are presented as
mean6S.E (n=4).
*indicates treatments affecting dimerization, i.e. with a calculated effect significantly different from 1 (p,0.1). Gefitinib increases dimerization in A431 cells and in EGF
treated SKOV3 cells, irrespective of FCS and pertuzumab.
doi:10.1371/journal.pone.0024739.t002
Table 3. The effect of pertuzumab on EGFR dimerization in A431 and SKOV3 cells.
A431
Without EGF With EGF
Effect of:
Complete
medium
Gefitinib+complete
medium
Gefitinib +serum
free medium
Complete
medium
Gefitinib+complete
medium
Gefitinib
+serum free
medium
Pertuzumab 0.960.2 1.160.3 1.560.1 1.060.0 1.560.1 1.160.1
SKOV3
Without EGF With EGF
Effect of:
Complete
medium
Gefitinib+complete
medium
Gefitinib +serum free
medium
Complete
medium
Gefitinib+complete
medium
Gefitinib
+serum free
medium
Pertuzumab 0.560.0* 0.560.1* 0.460.1* 0.560.0* 0.560.1* 0.660.1*
The table presents EffectValues, i.e. quotients of dimerization degrees. Lysates within the same gel treated identically apart from the exposure of pertuzumab were used
as references. Data are presented as mean6S.E (n=4).
*indicates treatments affecting dimerization, i.e. with a calculated effect significantly different from 1 (p,0.1). Pertuzumab disrupts approximately 50% of the
dimerization in SKOV3 cells, regardless of treatment of EGF, FCS or gefitinib. No effects of pertuzumab on EGFR dimerization in A431 cells are observed.
doi:10.1371/journal.pone.0024739.t003
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of the binding of
125I-EGF to EGFR on A431 and SKOV3 depicts
the impact of pertuzumab on association and dissociation rates,
thus establishing a connection between dimer quantities and
kinetic properties. In A431 and U343 cells, where the HER2 count
is about 10% of the EGFR count, no obvious effect of pertuzumab
was detected. Upon pertuzumab exposure in HER2 overexpress-
ing SKOV3 cells, the overall affinity decreased in gefitinib treated
Figure 3. The effect of lapatinib on the
125I-EGF–A431 interaction. The binding of
125I-EGF to cultured A431 cells treated with complete
medium (red), serum free medium (blue), 1 mM of lapatinib (A) or gefitinib (B) in complete medium (green) or 1 mM lapatinib (A) or gefitinib (B) in
serum free medium (black) was measured in LigandTracer Grey. A) Lapatinib alters the kinetics of the interaction, as shown as a faster overall
association rate and dissociation rate. In serum free medium, the difference between the first and second concentration (indicated by an arrow) is
slightly less. B) Gefitinib increases the affinity, observed as a slower dissociation rate and small difference in signal height between the first and
second concentration (arrow). The effect of gefitinib is larger in serum free medium.
doi:10.1371/journal.pone.0024739.g003
Figure 4. Heterogeneity and kinetic properties of simulated binding curves, presented as Interaction Maps. Interaction Maps were
calculated from simulated binding measurements to illustrate the ability to decipher complex interactions. The Interaction Maps display every
contributing interaction of the measured binding curve as a peak with specific recognition (log(ka)) and stability (log(kd)) coordinates using colors
representing the relative degree of contribution (red: large contribution, blue: small contribution). Panels A, B, and C contains maps for monovalent
interactions (CurveA, CurveB, CurveC). Panel D shows a map for the complex interaction CurveAB known to contain two independent interactions
(CurveA+CurveB). Panel E shows a map for the complex interaction CurveABC known to contain three independent interactions
(CurveA+CurveB+CurveC). The corresponding simulated binding curves are shown in Panel F. The binder was added first at 3 nM, then at 9 nM,
followed by dissociation during several hours, as indicated by the arrows.
doi:10.1371/journal.pone.0024739.g004
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in signal height between the first and second concentration in the
binding traces. In other words, pertuzumab seems to interrupt
most of the affinity enhancing effect of gefitinib. This indicates that
gefitinib may affect the
125I-EGF–EGFR interaction in SKOV3
by a process involving dimerization.
A goal in this project was to disrupt EGFR homodimerization as
well, in order to investigate its connection to the binding
characteristics of the
125I-EGF–EGFR interaction. However, no
agent was found that accomplish this without simultaneously
competing with EGF for the binding site (creating side effects
impossible to distinguish from homodimerization disruption
effects), thus this could not be established.
By the use of the cross-linking reagent BS
3, the dimers on the cell
surface will remain together during cell lysis and immunoblot
analysis [27]. In the cross-linking analysis presented in this paper,
EGFR dimers are visible without EGF stimulation in both A431
and SKOV3 cells, however to a low extent in A431 cells. The
increase ofa factor 4 upon EGFstimulationinA431 cellsaffirmsthe
hypothesis that EGF binding induces dimerization. On the other
hand,noimpactofEGFontheEGFR dimerizationinSKOV3cells
was detected, providing strength in the hypothesis of existing dimers
independent of EGF stimulation. The cell dependent matter of
dimerization may be due to differences in EGFR and HER2
receptor quantities. HER2 is known to spontaneously form
homodimers [28–29]. The findings in this paper indicate that this
applies also to EGFR–HER2 heterodimers. EGFR homodimeriza-
tion on the other hand, appears to require the presence of EGF, as
observed in EGFR-rich A431 cells.
In this study, complete medium containing FCS was used in
most assays. FCS is known to include some amount of growth
stimulators such as EGF, although this is assumed to be low and is
not expected to affect the outcome. Furthermore, FCS is often
included in similar studies by other groups, making the results
comparable.
The immunoblot results further highlight the impact of gefitinib
on the dimerization. Gefitinib increased EGFR dimerization in
A431 cells, more evidently in the absence of EGF where the
overall dimerization was comparably low. In SKOV3 cells on the
other hand, the impact of gefitinib was generally less. The
induction of EGFR dimers by gefitinib have been studied
previously. Yarden et al. proposed that the binding of gefitinib
stabilizes an active conformation of the kinase domain of EGFR,
creating ‘‘quasi-dimers’’ solely connected intracellularly [21].
Gefitinib is known to prevent growth in both A431 and SKOV3
cells [30], suggesting that the tyrosine kinase activity of the
induced EGFR dimers are inhibited, but this does not specify
whether they resemble the naturally formed dimers or not. The
impact of gefitinib on the kinetics of the extracellular interaction
with
125I-EGF [22] indicates that the increased dimerization is
more than an intracellular phenomenon although further
conclusions about the nature of the dimers are difficult to draw.
Figure 5. Heterogeneity and kinetic properties of the
125I-EGF–EGFR interaction, presented as Interaction Maps. Interaction Maps
were calculated from real-time binding measurements of the interaction between
125I-EGF and A431 (A–C) or SKOV3 (D–F) cells, using complete
medium (A and D), gefitinib in serum free medium (B and E) or gefitinib in serum free medium in the presence of pertuzumab (C and E). A) Under
normal conditions in A431 cells, a fast on–fast off (A1: [4.79,23.25]) and a slow on–slow off (A2: [3.98,24.94]) interaction are observed. B) When
treated with gefitinib in serum free medium, the more stable peak (A2) is slightly shifted to a higher recognition (B2: [4.37,24.96]), but more
importantly another peak at [6.11,25.28] (B3) appears. C) The coordinates and the contributions of the different peaks are approximately the same
with pertuzumab as without, indicating no effect of pertuzumab on the binding of
125I-EGF in A431 cells. D) The binding of
125I-EGF to SKOV3 cells at
normal conditions consists of two interactions at [4.85,24.59] (D2) and [5.07,23.48] (D1), the latter less contributing. E) For gefitinib and serum free
treated SKOV3 cells, the more stable interaction (D2) is shifted to even higher stability (E2: [4.89,25.82]) while the contribution of the other
interaction is reduced (E1). F) The Interaction Map of gefitinib and serum free treated SKOV3 cells in the presence of pertuzumab seems to be a
mixture of Interaction Maps D and E.
doi:10.1371/journal.pone.0024739.g005
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gefitinib treated cells. This indicates that the effect of serum free
medium to the kinetics of the interaction between
125I-EGF and
gefitinib treated A431 cells cannot be explained by dimerization
variation or is too small to be detected by immunoblotting.
The HER2 dimerization inhibitor pertuzumab did not affect
the overall EGFR dimerization in A431 cells to a detectable
degree, regardless of EGF stimulation, indicating that the EGFR
dimers on A431 cells are mostly homodimers. In SKOV3 cells on
the other hand, EGFR dimerization drops to 50% upon
pertuzumab treatment. The pertuzumab concentration used in
the experiment (20 nM) will prevent approximately 75–85% of the
HER2 population to form dimers [32], which explains that there
are still visible amounts of EGFR dimers in SKOV3 cells. Other
factors, like EGFR forming heterodimers with HER3 or HER4 as
binding partners are possible but less likely because these receptors
are believed to be expressed in much lower levels and are assumed
not to affect the outcome much [31]. On the whole, pertuzumab
clearly reduces EGFR dimerization.
The combination of pertuzumab and gefitinib is interesting.
Looking at the numbers in Table 2 and 3, gefitinib doubles the
amount of EGFR dimers in EGF stimulated SKOV3 cells, while
pertuzumab simultaneously decreases the amount to 50%. The
counteraction of pertuzumab on the gefitinib effect was visible in
the real-time interaction data of
125I-EGF–SKOV3 as well, yet
again suggesting dimerization as a strong contributor to the
mechanism of action of gefitinib on the extracellular binding of
EGF. As pointed out earlier, it is unclear to what extent EGFR
forms heterodimers and homodimers in the cells. Gefitinib may
induce solely EGFR homodimers and pertuzumab disrupts
EGFR–HER2 dimers but may increase EGFR homodimers. This
way, the dimers observed for cells in normal conditions (Fig. 1A,
black curve) and when exposed to a combination of gefitinib and
pertuzumab (Fig. 1C and D, red curves) may be of different
nature, possibly creating the small but visible difference in
interaction kinetics observed in the real-time interaction data.
The measurement of the effect of lapatinib on the binding of
125I-EGF to A431cells complements the gefitinib study. Lapatinib
binds the inactive forms of EGFR and HER2 and does not induce
EGFR dimers as opposed to gefitinib that stabilize the active
conformation of EGFR [18,19,20,21]. In this paper, real-time
interaction data shows that lapatinib affects the binding of
125I-
EGF, demonstrating that there are other examples of intracellular
binders with the potential to influence extracellular interactions.
However, the effect of lapatinib on the kinetic properties was
unlike what was observed for gefitinib, indicating that the
mechanism of action is different between the two tyrosine kinase
inhibitors. This strengthens the hypothesis that the generation of
EGFR dimers, not observed for lapatinib, is an important part of
the effect of gefitinib on the
125I-EGF binding. By binding and
stabilizing the inactive conformation of EGFR, lapatinib may
alternatively inhibit EGFR dimerization, as suggested from the
clear, but different, shape of the real-time binding curve.
Interaction Map analysis opens up possibilities for speculation.
The two to three visible peaks in each of the Interaction Maps in
Figure 5 demonstrate a heterogeneous nature of the binding of
EGF to EGFR and provide a detailed description of both the
contribution and kinetic properties of the simultaneously occurring
interactions. One peak at approximately [5, 23.5] is visible in all
six Interaction Maps (A1, B1, C1, D1, E1, F1). A peak
representing a more stable interaction is observed as well (A2,
B2, C2, D2, E2, F2), but it changes in position and contribution
between treatments and cell lines and may even be divided into
two peaks in the gefitinib treated A431 cells (B3, C3). One
hypothesis is that the right-most peaks (A1–F1) visible in all
treatments correspond to the binding of
125I-EGF to monomeric
EGFR and that the more stable peaks (A2–F2, B3, C3) observed in
the left parts of the Interaction Maps represent the interaction
between
125I-EGF and its two major dimeric forms. The
comparably low amount of HER2 receptors in A431 cells makes
HER2 an unlikely dimerization partner, leaving EGFR as
monomers and homodimers. In SKOV3 cells on the other hand,
the large HER2 count will likely ‘‘consume’’ most EGFR
receptors, shifting the equilibrium to a more heterodimeric state
(Fig. 6A). The differences in A2 and D2 may thus represent the
two types of EGFR dimer types. This peak is altered in the
presence of the dimerization altering factors gefitinib and
pertuzumab, strengthening the idea of it representing the dimeric
state. If this hypothesis is valid, Figures 5B and 5E shows that
gefitinib induces a shift in contribution from a monomeric state
towards a dimeric. It also alters the interaction of EGF with the
dimeric form, observed as a new fast on–slow off peak (B3, C3) in
A431 cells and a change towards higher stability (from D2 to E2)
in SKOV3 cells. The effect of pertuzumab (Fig. 5C and F)
indicates that the gefitinib induced dimers are still mostly
homodimers in A431 cells (unaffected by pertuzumab) and
heterodimers in SKOV3 cells (clearly affected by pertuzumab)
(Fig 6B). One necessary experiment for verifying the accuracy of
this hypothesis would be to distinguish between EGFR homodi-
mers and EGFR–HER2 heterodimers, in normal conditions and
upon gefitinib treatment. Gefitinib is directed towards EGFR [33],
suggesting that the induced dimers are solely EGFR homodimers
if presuming the need of gefitinib binding to both binding partners
for a functioning dimerization. However, kinase inhibitors are
notoriously promiscuous [34] and it is possible that gefitinib also
binds to HER2 to some extent.
The question remains whether EGF can bind to pre-existing
EGFR dimers or if the differences in interaction are merely the
result of EGF dissociating from either EGFR monomers or dimers.
The observed association rate of a ligand to its target will relate to
the recognition and stability of the interaction and the concentra-
tion of the ligand, while the observed dissociation rate is dependent
on the stability alone [35]. The differences in stability between the
observed peaks can thus represent various forms of dissociation. In
A431 cells there are differences in recognition as well, indicating
that EGF is able to not only dissociate from, but also associate to at
least two different structures. Our hypothesis is that these
structures are EGFR monomers and EGFR dimers, i.e.
125I-
EGF binds independently and directly to both EGFR monomers
and existing EGFR homo/hetero dimers on A431 cells.
One of the goals of this paper was to establish the biological
processes behind the effect of the tyrosine kinase inhibitor gefitinib
on the EGF–EGFR interaction. We propose that gefitinib induces
dimers with higher affinity to
125I-EGF than EGFR monomers or
the EGFR dimers normally displayed on the cell surface.
Furthermore, the heterogeneity of the
125I-EGF–EGFR interac-
tion proposes an explanation to the previously observed differences
in affinity between cell lines. The epidermal growth factor
receptors may be identical in both sequence and tertiary structure,
but to what extent they form dimers may depend on e.g. the
receptor expression of the hosting cell line. Each EGFR
monomer/dimer form interacts with EGF with specific kinetics
properties (recognition and stability), which results in differences in
overall affinity depending on the prevalence of these interactions.
Interaction Maps can decipher a measured interaction into its
contributing components, thus opens up for a detailed under-
standing of the EGFR family puzzle.
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gefitinib induces formation of EGFR dimers which alters the
apparent interaction characteristics with EGF. The prevalence of
monomers, homodimers and heterodimers are different between
cell lines and are likely dependent on EGFR and HER2
expression. EGF binds to the various monomeric/dimeric forms
of EGFR with unique binding properties, thus the distribution of
the different EGFR forms in a cell will affect the overall affinity.
Materials and Methods
Antibodies and reagents
The tyrosine kinase inhibitors gefitinib and lapatinib was from
Biaffin GmbH (Kassel, Germany) and GlaxoSmithKline (London,
UK) respectively. Cetuximab was purified from ErbituxH (Merck
KGaA, Darmstadt, Germany) and trastuzumab was purified from
HerceptinH (Roche AB, Stockholm, Sweden). The humanized
monoclonal antibody pertuzumab, directed towards HER2 to
prevent dimerization, was purified from Omnitarg
TM from
Genentech (San Fransisco, CA, USA). The cross-linking reagent
bis(sulfosuccinimidyl)suberate (BS
3) was purchased from Thermo
Scientific (Rockford, IL, USA). The polyclonal rabbit anti-EGFR
antibody was from Santa Cruz (Santa Cruz, CA, USA) and the
monoclonal mouse anti-b-actin antibody (clone AC-15) was from
Sigma Aldrich (St Louis, MO, USA). Peroxidase-conjugated anti-
rabbit antibody and peroxidase-conjugated anti-mouse antibody
was purchased from GE Healthcare (Waukesha, WI, USA).
Cell culture
Four cell lines were used: the human squamous carcinoma cell
line A431 (CLR 1555, ATCC, Rocksville, MD, USA), the human
ovarian carcinoma cell line SKOV3 (HTB-77, ATCC, Rocksville,
MD, USA) the human glioma cell line U343MGaCl2:6 (a subclone
of U343MG [36]), denoted U343, and the human breast cancer cell
line SKBR3(HTB-30,ATCC,Rocksville,MD,USA).Inallcellular
experiments, the cells were grown in a humified incubator at 37uC,
equilibrated with 5% C02 until experimental day. The cells were
cultured in Ham’s F10 cell culture medium (Biochrom Ag, Berlin,
Germany) supplemented with 10% fetal calf serum (Sigma, St
Louis, MO, USA), L-glutamine (2 mM) and PEST (penicillin
100 IU/ml and streptomycin 100 mg/ml, from Biochrom Ag,
Berlin Germany) if not otherwise specified.
Radiolabeling
Human Epidermal growth factor (EGF, Chemicon Internation-
al, USA) was labeled with
125I (Perkin-Elmer, Wellesley, MA,
USA) using the Chloramine-T protocol [37].
Treatment of cells with tyrosine kinase inhibitors
Cells were exposed to four different treatments, as described
previously [22]. In brief, cells were incubated for 24248 h in
either complete or serum free Hams F10 culturing medium in the
presence or absence of 1 mM of either gefitinib or lapatinib.
Estimating number of receptors
The expression levels of EGFR and HER2 were estimated using
either the manual or the kinetic extrapolation (KEX) method, as
described by Ba ´rta et. al. [24]. For the manual protocol, cells were
seeded in triplicates in 12-wells plates (NuclonTM, Roskilde,
Denmark).
125I-labeled cetuximab and trastuzumab were used for
the quantification of EGFR and HER2 respectively. A single
concentration of 100 nM antibody was estimated to be sufficient
for saturating the receptors, as it corresponds to approximately
1006KD. After 3–4 hours of incubation at 4 uC, the cells were
washed repeatedly with serum free medium, followed by trypsination.
The number of resuspended cells were counted and the radioactivity
measured (automatic gamma counter 1480 WIZARD
TM 3’’,
PerkinElmer) to evaluate cell receptor levels [38]. For the KEX
method, cells were incubated with increasing concentrations of either
125I-labeled trastuzumab or cetuximab in LigandTracer Grey at
room temperature. The binding traces were to a kinetic model
describing a bivalent interaction, using TraceDrawer 1.2 (Ridgeview
Instruments AB, Uppsala, Sweden). This resulted in an estimation of
Bmax, which was used to correct for non-saturation of receptors.
Real-time interaction measurements of
125EGF in
LigandTracer
Real-time measurements of the binding of
125I-EGF to EGFR
on the cells were performed at room temperature in LigandTracer
Grey instruments, according to previously published protocol [39].
After a short baseline, the cells were incubated for 3.5 h twice
using increasing concentrations of
125I-EGF. The concentrations
were chosen based on the affinity to EGF for the three cell lines
Figure 6. Proposed mechanism of EGF binding to EGFR in
normal conditions and when treated with gefitinib. A) Real-time
binding data of
125I-EGF to A431 and SKOV3 cells, as presented in
Interaction Maps, depicts a reality where EGF interacts with not only
one receptor form, but several. The different receptor populations may
be the monomeric, heterodimeric and homodimeric form of EGFR. The
equilibration between the different monomer/dimer states will likely be
dependent on the number of EGFR and HER2 receptors expressed on
the cell surfaces, where a large HER2 count shifts the equilibrium to
more EGFR–HER2 heterodimers and a high EGFR expression results in
more EGFR homodimers. Differences in stability of the interaction imply
that EGF can dissociate from all three forms. The ability of EGF to bind
to ligand free dimers (dashed lines) remains unclear, as the existence of
such dimers. B) When treated with gefitinib, the binding of EGF to the
dimeric form is altered, suggesting that a new dimeric form is created,
either as an addition (A431) or as a replacement (SKOV3).
doi:10.1371/journal.pone.0024739.g006
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for SKOV3). The ligand solution was replaced with fresh medium
(containing 1 mM gefitinib or 1 mM lapatinib in the TKI treatment
studies) and the dissociation rate was followed over night.
Dimerization perturbation
To prevent EGFR-HER2 dimerization, A431, SKOV3 and
U343 cells were incubated with 20 nM of pertuzumab over night
prior to the detection of the
125I-EGF – EGFR interaction in
LigandTracer Grey or the cross-linking experiments. The
antibody remained in the
125I-EGF solution during measurement
(LigandTracer) or EGF incubation (cross-linking). Pertuzumab
effects were studied in combination with four of the treatments
described above (complete medium, serum free medium, 1 mM
gefitinib and serum free medium+gefitinib).
Cross-linking of EGFR and HER2
Prior to cross-linking, the cells were treated with or without
1 mM gefitinib (48 h) and 20 nM pertuzumab (over-night) in 37uC
as described previously, followed by incubation with or without
EGF (9 nM) for 3.5 hours at room temperature. After three times
washing with ice cold PBS, the cells were subjected to 1 mM of the
cross-linking reagent BS
3at room temperature for 30 min. The
reaction was terminated using 20 mM (final concentration) Tris-
Cl, pH 8.5 for 15 min at room temperature. Subsequently, cells
were washed with ice cold PBS and solubillized in lysis buffer
containing 150 mM NaCl, 20 mM Tris(amino), 5 mM EDTA,
10% (v/v) glycerol and 1% (v/v) Triton X-100 and a cocktail of
protease and phosphatase inhibitors.
Immunoblotting and image analysis
Cell lysates were separated by SDS-PAGE in a 3–8% tris-
acetate gel (Invitrogen, Carlsbad, CA, USA) and transferred to
PVDF membranes (Millipore Corporation, Billerica, MA, USA),
which were blocked for 1 h with PBS-T with 5% BSA (w/v) before
incubation with primary antibodies at 4uC over-nigh. The proteins
were visualized using peroxidase-conjugated ImmobilionTM
Western Chemiluminescent HRP Substrate (Millipore Corpora-
tion, Billerica, MA, USA) in a cooled charge-coupled device
(CCD) camera (FujiFilm, Luminescent Image analyzer LAS-
1000plus). The intensity of bands was quantified in ImageJ
(Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997–2011)
to study the consequences of treatments upon dimerization.
Statistical analysis was performed in MinitabH 15 (Minitab Inc.,
State College, PA, USA) using Student’s t-tests. Results with p-
values less than 0.1 were deemed significant. The HiMark
TM
(Invitrogen, Carlsbad, CA, USA) molecular weight protein
standards ranging from 31 kDa to 460 kDa was used to assess
the molecular weight of identified bands.
Interaction Map analysis
The mathematical method Interaction Map [25] expresses the
measured binding of a (homogeneous) ligand to a heterogeneous
group of targets as a sum of interactions, each having a unique
combination of the association rate constant ka and dissociation
rate constant kd:
MeasuredCurve~
X n
i~1
X m
j~1
Wij|CurveComponent conc,ki
a,k
j
d
   hi
where conc is the concentration of protein in solution (the
‘‘ligand’’) and Wij is the weighing factor describing the
contribution to the measured real-time interaction curve. The
calculated contributing curves are represented as colored (red=-
large Wij, dark blue=small Wij) peaks in an on-off plot. In this
paper, the Interaction Map method used 24 (ka)630 (kd) different
nodes with kinetic parameter values evenly distributed in log-space
(log10(ka)={2.0000, 2.2609, 2.5217, …, 7.4783, 7.7391, 8.0000} ,
log10(kd)={-6.0000, 25.8276, 25.6552, …, 21.3448, 21.1724,
21.0000}). A Tichonov-type regularization algorithm was used to
real-time binding curves measured in LigandTracer Grey, adding
penalty to the sum-of-square residuals if there are many peaks in
the Interaction Map. A similar algorithm has been presented
previously [23] and has been applied to SPR-based real-time
interaction analysis.
The non-linear fitting algorithm was implemented in Visual
Basic/Visual Studio 2003 (Microsoft, Mountain View, CA). The
ability of the Interaction Map algorithm to accurately decompose
a complex binding data was validated on a series of binding curves
simulated in MATLAB 6.5 (The Mathworks, Natic, MA, USA).
The peak position was estimated as the center of gravity for the
peak and is reported as [log10(ka) , log10(kd)]. The contribution of
a peak was estimated as the percentage of the weight factors (Wij)
for the pixels of the peak in comparison to the sum of all weight
factors.
The interactionmap algorithmwas tested usinga range ofdifferent
simulated binding curves with known interaction properties. In this
paper, simulated curves with similar binding properties as what was
found in the investigated
125I-EGF - EGFR interaction were used:
monovalent CurveA (ka=10
5 M
21s
21;k d=5*10
24 s
21), monova-
lent CurveB (ka=5*10
4 M
21s
21;k d=10
25 s
21), monovalent Cur-
veC (ka=8*10
5 M
21s
21;k d=8*10
26 s
21), complex CurveAB
(CurveA+CurveB) and complex CurveABC (CurveA+CurveB+Cur-
veC). In all cases, an assay of first 2 h of 3 nM binder, then 2 h of
9 nM binder and finally 6 h of dissociation (i.e. 0 nM binder) was
simulated. Noise corresponding to 1% of the signal was added to each
curve. These five curves were subjected to Interaction Map analysis
and were expected to produce single, double or triple peak maps.
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